search
Back to results

Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis

Primary Purpose

Multiple Sclerosis, Gait Disorders, Neurologic

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ekso GT™ exoskeleton
Sponsored by
The Cleveland Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of MS per 2017 revised McDonald criteria
  • EDSS score 5.5-7.5 (moderate to severe walking disability)
  • Cleared for gait training with the study device by the study treating physician

Device-Specific Criteria

  • Involved in a standing program or must be able to tolerate at least 15 min upright without signs or symptoms of orthostatic hypotension
  • Weigh 220 pounds (100kg) or less
  • Be able to fit into the Ekso device:
  • Between approximately 5'0" and 6'4" tall (really depends on leg measurements)
  • Sufficient diaphragmatic strength such that respiration is not compromised with exercise

Assessed by physical therapy:

  • Standing hip width of approximately 18" or less
  • Have near normal range of motion(ROM) in hips, knees and ankles
  • Sufficient upper extremity strength to use a front wheeled walker by manual muscle testing (minimum triceps strength bilaterally of 3/5, shoulder abduction and flexion/extension of 4/5 OR as discussed during demo, 2 normally functioning limbs such as in hemiplegia)

Exclusion Criteria:

  • • MS exacerbation, severe acute comorbidity or surgery less than 90 days prior to enrollment

    • Diagnosed with osteoporosis or history of long bone fractures since diagnosis
    • Safety concern due to neurologic impairments (e.g. upper extremity weakness, visual loss) or comorbidities (e.g. cardiac, respiratory)
    • Other neurologic or non-neurologic condition interfering with walking
    • < 1 month since previous intensive gait training regimen or initiation of treatment that can affect walking (e.g. medication for spasticity)
    • Planned change in medications that may affect walking during the study period
    • Uncontrolled or severe orthostatic hypotension that limits standing tolerance
    • Active heterotrophic ossification (HO), hip dysplasia, or uncontrolled hip/knee axis abnormalities
    • Score <22 on the Mini-Mental State Examination or deemed to have cognitive impairment precluding safe training with the device during the screening and training process
    • Colostomy
    • Pregnancy
    • Unresolved deep vein thrombosis
    • Uncontrolled autonomic dysreflexia
    • Currently involved in another rehabilitation study

Assessed by physical therapy:

  • Severe spasticity that prevents joint motion (severe stiffness or rigidity) in proximal lower extremity muscles, including hip adductors and knee flexors/extensors.
  • Hip flexion contracture greater than ~17°
  • Knee flexion contracture greater than 12°
  • Unable to achieve neutral ankle dorsiflexion with passive stretch (achieve neutral with up to 12° knee flexion)
  • Leg length discrepancy greater than 0.5" for upper leg, greater than 0.75" for lower leg
  • Spinal instability
  • Severe muscular or skeletal pain
  • Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton or harness
  • Shoulder extension range of motion(ROM) < 50° excludes using crutches during sit to stand or vice versa. (Walking with crutches permitted, sit <> stand would be done with walker

Sites / Locations

  • Cleveland Clinic Neurological Institute Mellen Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

gait training with exoskeleton device

Arm Description

uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton

Outcomes

Primary Outcome Measures

Dropout Rate
Percentage of enrolled participants who drop out of the study before the end of the treatment period.
Adverse Events
.All adverse events were collected throughout the study for each participant, up to 14 weeks",

Secondary Outcome Measures

Timed 25 Foot Walk
Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.

Full Information

First Posted
June 6, 2019
Last Updated
June 24, 2022
Sponsor
The Cleveland Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT04000373
Brief Title
Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
Official Title
Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
July 23, 2019 (Actual)
Primary Completion Date
January 9, 2020 (Actual)
Study Completion Date
January 9, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Cleveland Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™) exoskeleton for gait training in MS patients. The device will solely be used in the clinic under direct supervision from a physical therapist. This is a small PI-initiated uncontrolled pilot study to gather safety and feasibility data on the exoskeleton in individuals with MS and walking impairment.
Detailed Description
Powered exoskeletons are approved by the FDA to assist in the rehabilitation of persons with spinal cord injury and post-stroke hemiplegia. The investigator is aware of only one pilot study of a powered exoskeleton (ReWalk®) in multiple sclerosis (MS) which demonstrated some improvements in sitting, standing and walking posture when used consistently. The investigator is not aware of any study of the Ekso GT™ exoskeleton in MS. This is a feasibility and safety study of using the Ekso GT™ exoskeleton for gait training in patients with relapsing or progressive MS and severe mobility limitations (EDSS 5-5 - 7.5). Preliminary efficacy outcomes on gait and walking will also be collected for the purpose of designing a larger clinical trial of the Ekso GT™ exoskeleton for gait training in patients with MS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis, Gait Disorders, Neurologic

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
uncontrolled pre-post intervention study of the use of the Ekso GT™exoskeleton in gait training in the MS population
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
gait training with exoskeleton device
Arm Type
Other
Arm Description
uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Intervention Type
Device
Intervention Name(s)
Ekso GT™ exoskeleton
Intervention Description
The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
Primary Outcome Measure Information:
Title
Dropout Rate
Description
Percentage of enrolled participants who drop out of the study before the end of the treatment period.
Time Frame
0-14 weeks
Title
Adverse Events
Description
.All adverse events were collected throughout the study for each participant, up to 14 weeks",
Time Frame
0-14 weeks
Secondary Outcome Measure Information:
Title
Timed 25 Foot Walk
Description
Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.
Time Frame
0-14 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of MS per 2017 revised McDonald criteria EDSS score 5.5-7.5 (moderate to severe walking disability) Cleared for gait training with the study device by the study treating physician Device-Specific Criteria Involved in a standing program or must be able to tolerate at least 15 min upright without signs or symptoms of orthostatic hypotension Weigh 220 pounds (100kg) or less Be able to fit into the Ekso device: Between approximately 5'0" and 6'4" tall (really depends on leg measurements) Sufficient diaphragmatic strength such that respiration is not compromised with exercise Assessed by physical therapy: Standing hip width of approximately 18" or less Have near normal range of motion(ROM) in hips, knees and ankles Sufficient upper extremity strength to use a front wheeled walker by manual muscle testing (minimum triceps strength bilaterally of 3/5, shoulder abduction and flexion/extension of 4/5 OR as discussed during demo, 2 normally functioning limbs such as in hemiplegia) Exclusion Criteria: • MS exacerbation, severe acute comorbidity or surgery less than 90 days prior to enrollment Diagnosed with osteoporosis or history of long bone fractures since diagnosis Safety concern due to neurologic impairments (e.g. upper extremity weakness, visual loss) or comorbidities (e.g. cardiac, respiratory) Other neurologic or non-neurologic condition interfering with walking < 1 month since previous intensive gait training regimen or initiation of treatment that can affect walking (e.g. medication for spasticity) Planned change in medications that may affect walking during the study period Uncontrolled or severe orthostatic hypotension that limits standing tolerance Active heterotrophic ossification (HO), hip dysplasia, or uncontrolled hip/knee axis abnormalities Score <22 on the Mini-Mental State Examination or deemed to have cognitive impairment precluding safe training with the device during the screening and training process Colostomy Pregnancy Unresolved deep vein thrombosis Uncontrolled autonomic dysreflexia Currently involved in another rehabilitation study Assessed by physical therapy: Severe spasticity that prevents joint motion (severe stiffness or rigidity) in proximal lower extremity muscles, including hip adductors and knee flexors/extensors. Hip flexion contracture greater than ~17° Knee flexion contracture greater than 12° Unable to achieve neutral ankle dorsiflexion with passive stretch (achieve neutral with up to 12° knee flexion) Leg length discrepancy greater than 0.5" for upper leg, greater than 0.75" for lower leg Spinal instability Severe muscular or skeletal pain Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton or harness Shoulder extension range of motion(ROM) < 50° excludes using crutches during sit to stand or vice versa. (Walking with crutches permitted, sit <> stand would be done with walker
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francois A Bethoux, MD
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Neurological Institute Mellen Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis

We'll reach out to this number within 24 hrs